Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome

• A randomized, placebo-controlled study of 1000 mg ferric carboxymaltose (FCM) in restless legs syndrome (RLS) patients was conducted.• FCM recipients had significant improvement in RLS symptoms at the 6-week endpoint.• More than one-third of FCM recipients were still not requiring RLS medications at 30 weeks.

from #ENT via xlomafota13 on Inoreader http://ift.tt/2c1CYsl
via IFTTT